<DOC>
	<DOC>NCT01353053</DOC>
	<brief_summary>The aim of this the study is to the assess whether the graft and patient survival, rejection rates and renal graft function after the first year will not differ between both study arms. The investigators will also the evaluate the reduction in the incidence of cytomegalovirus the and improvement of renal function of the everolimus after 1 year.</brief_summary>
	<brief_title>Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Patients with BMI below 30, first transplants with PRA &lt; 30, no contraindication for induction Thymoglobuline, age 18 years or younger than 70 years. patients with a BMI above 30 retransplantation patients hypersensitized with PRA &gt; 30 compared with Thymoglobulina indication for induction age under 18 or over 70 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Renal Transplant</keyword>
	<keyword>Atrophy/interstitial</keyword>
	<keyword>Conversion of tacrolimus everolimus</keyword>
</DOC>